- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | Coeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application | 104 | GlobeNewswire (Europe) | ~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company")... ► Artikel lesen | |
| 19.03. | Coeptis Therapeutics Holdings, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 09.03. | Coeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build | 1.171 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / March 9, 2026 / When Coeptis Therapeutics Holdings, Inc. (Nasdaq:COEP) and Z Squared Inc. announced their transformational merger in April 2025, the process ahead was... ► Artikel lesen | |
| 12.02. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| COEPTIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.02. | Coeptis Therapeutics: Coeptis Receives Shareholder Approval Towards Z Squared Merger | 216 | GlobeNewswire (Europe) | WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced... ► Artikel lesen | |
| 04.02. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform | 602 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / February 4, 2026 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shareholders approved a transformational merger that converts a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 16.01. | NASDAQ rügt Coeptis Therapeutics wegen verspäteter Hauptversammlung | 1 | Investing.com Deutsch | ||
| 16.01. | Coeptis Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Coeptis Therapeutics Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes Coverage | 413 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / January 6, 2026 / The Vanderbilt Report today published coverage of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) following the company's recent SEC filings detailing... ► Artikel lesen | |
| 06.01. | Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared | 179 | GlobeNewswire (Europe) | WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company,, announced today... ► Artikel lesen | |
| 22.12.25 | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 10.12.25 | Coeptis Therapeutics Holdings, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 01.10.25 | Coeptis Therapeutics: Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage | 315 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent... ► Artikel lesen | |
| 25.04.25 | Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement | 353 | GlobeNewswire (Europe) | WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) ("Coeptis" or the "Company"), a biopharmaceutical and technology company focused on developing innovative... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,40 | 0,00 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| KYMERA THERAPEUTICS | 86,93 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| DISC MEDICINE | 71,41 | -0,45 % | Disc Medicine Inc: Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,610 | -1,58 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 16,580 | 0,00 % | Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | ||
| ERASCA | 21,700 | 0,00 % | Jefferies reiterates Erasca stock Buy rating ahead of ASCO data | ||
| ENVERIC BIOSCIENCES | 3,575 | 0,00 % | Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? | ||
| PSYENCE BIOMEDICAL | 11,210 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,410 | -3,44 % | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market | ||
| HARMONY BIOSCIENCES | 29,530 | -1,53 % | Dravet-Syndrom: Harmony Biosciences präsentiert neue Studiendaten | ||
| ARRIVENT BIOPHARMA | 31,390 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,120 | 0,00 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| ARCELLX | 115,01 | 0,00 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,470 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading... ► Artikel lesen | |
| CLIMB BIO | 8,970 | -1,86 % | Mizuho nimmt Coverage für Climb Bio-Aktie mit "Outperform"-Rating auf |
Das Unternehmen COEPTIS THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +1,260 (+8,82 %) liegt der Kurs bei 15,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COEPTIS THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.